Predictive Marker in Nonmetastatic Renal Cell Carcinoma After Nephrectomy
Posted: Friday, September 1, 2017
Preoperative measurement of serum C-reactive protein and albumin levels with the modified Glasgow Prognostic Score (mGPS) appears to be a reliable predictive marker of survival in patients with nonmetastatic renal cell carcinoma before nephrectomy. Takuya Tsujino, MD, of Osaka Medical College in Takatsuki City, Japan, and colleagues, who reported their findings in the Annals of Surgical Oncology, believe that mGPS should be considered when making treatment decisions for these patients.
The investigators collected clinicopathologic and follow-up data on 219 patients with renal cell carcinoma, all of whom underwent nephrectomy. The 5-year overall survival rate was 85.9% for nonmetastatic patients (n=195) and 18.8% for metastatic (n=24) patients.
Although an increasing mGPS was linked to shorter overall survival in those with nonmetastatic disease, there was no major difference in overall survival according to mGPS in those with metastatic disease. Furthermore, based on a multivariate analysis, the mGPS remained an independent predictor of overall and cancer-specific survival in patients with nonmetastatic renal cell carcinoma.